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Dr Meduri and colleagues, in their comment “Steroid
treatment in ARDS: a highly effective treatment” [1], written in
response to the article of Wajanaponsan et al. [2], described
data and an adjusted analysis provided by the Acute
Respiratory Distress Syndrome (ARDS) Network (as a
personal communication). We wish to comment on their
assertion of large imbalances between the treatment and
steroid arms in the cohort of participants randomized after
13 days of ARDS and suggest a word of caution for
interpreting this post hoc analysis.
Among our small subset of 48 patients randomized after
13 days of ARDS, only one of 43 baseline variables was
statistically imbalanced between control and methylpred-
nisolone (MPS) [3]. Partial pressure of arterial oxygen/fraction
of inspired oxygen (P/F) ratios were similar (126 versus 128,
control versus MPS). Mean age (45.2 versus 52.5) and Acute
Physiology and Chronic Health Evaluation (APACHE) III (79
versus 87) were higher in the MPS group, but the differences
were well within the range of random variation. When
adjusted for multiple comparisons there were no statistical
differences between two treatment arms.
Moreover, the lung injury score (LIS) was missing in over a
third of patients and was based on compliance and P/F ratio
only. We apologize for not making this apparent in our
communication with Dr Meduri. The Murray LIS, which uses
the number of chest X-ray quadrants and levels of positive
end expiratory pressure in addition to compliance and P/F
ratio, allows for missing values and is available for most
patients [4]. This score was not significantly different
(3.0 ± 0.5 versus 3.2 ± 0.5, p = 0.3239).
The adjusted analysis we provided for Dr Meduri of mortality
in the subgroup of 48 patients enrolled after 13 days of
ARDS was based on a set of variables derived from our prior
trials and reported by us as significant for prediction of
mortality in ARDS/acute lung injury (baseline APACHE III,
age, plateau pressure, baseline number of organ failures, and
baseline alveolar to arterial oxygen difference [A-aDO2]) [5].
With this adjustment, no statistical difference in mortality was
seen between treatment arms for patients randomized after
14 days (11.2% for placebo versus 28.0% for MPS,
p = 0.57, adjusted, compared to 12% for placebo versus
44% for MPS, p = 0.01, unadjusted). When the Murray LIS is
added to the model, the p value is 0.22. At Dr Meduri’s
request, we performed a third adjustment by adding
pneumonia, gender, and creatinine to the model. The results
are similar to the first adjustment (mortality 13.2% for placebo
and 25.6% for MPS; p = 0.325).
A more appropriate statistical test is a test of interaction
between the onset of treatment (placebo versus MPS) and
the duration of ARDS (7 to 13 days versus 14+ days). This
test addresses the hypothesis that the effect of MPS is
similar before and after two weeks of ARDS. Our a priori
planned test for interaction was unadjusted and was positive
(p = 0.0170) as reported [3]. We repeated the analysis using
a logistic regression model that included treatment arm,
duration of ARDS and their interaction, as well as APACHE
III, age, plateau pressure, number of organ failures, A-aDO2,
and the Murray LIS. The adjusted interaction p value is
p = 0.0878. Because this is a safety issue, we still think these
results provide reasons for concern for a harmful effect of
MPS on mortality later in the course of ARDS.
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In any randomized clinical trial the primary device for
equalizing populations between treatment groups is random
assignment of treatments, and this includes subgroups
defined by pre-randomization variables. We feel that all the
adjusted analyses and the a priori unadjusted analyses
support our original concern that “starting methylpred-
nisolone therapy more than two weeks after the onset of
ARDS may increase the risk of death” [3]. The possibility of
harm with late administration of corticosteroids has implica-
tions for future trials of MPS. Crossover designs where
placebo non-responders receive corticosteroids later in their
course may have the effect of increasing placebo mortality
leading an apparent, but not necessarily real, benefit of MPS
in the intention to treat (or as randomized) analysis.
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